Edap TMS SA (EDAP)
7.07
0.00 (0.00%)
USD |
NASDAQ |
May 10, 16:00
7.07
0.00 (0.00%)
After-Hours: 20:00
Edap TMS Enterprise Value: 220.92M for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 09, 2024 | 220.92M |
May 08, 2024 | 222.03M |
May 07, 2024 | 222.03M |
May 06, 2024 | 221.29M |
May 03, 2024 | 223.52M |
May 02, 2024 | 230.94M |
May 01, 2024 | 222.03M |
April 30, 2024 | 219.81M |
April 29, 2024 | 227.97M |
April 26, 2024 | 228.71M |
April 25, 2024 | 233.17M |
April 24, 2024 | 212.39M |
April 23, 2024 | 221.66M |
April 22, 2024 | 223.89M |
April 19, 2024 | 227.97M |
April 18, 2024 | 223.15M |
April 17, 2024 | 231.68M |
April 16, 2024 | 229.46M |
April 15, 2024 | 234.28M |
April 12, 2024 | 239.47M |
April 11, 2024 | 249.49M |
April 10, 2024 | 265.45M |
April 09, 2024 | 273.98M |
April 08, 2024 | 268.04M |
April 05, 2024 | 260.99M |
Date | Value |
---|---|
April 04, 2024 | 252.46M |
April 03, 2024 | 246.89M |
April 02, 2024 | 239.47M |
April 01, 2024 | 239.10M |
March 28, 2024 | 231.31M |
March 27, 2024 | 222.03M |
March 26, 2024 | 229.46M |
March 25, 2024 | 233.17M |
March 22, 2024 | 233.35M |
March 21, 2024 | 233.17M |
March 20, 2024 | 238.36M |
March 19, 2024 | 238.73M |
March 18, 2024 | 227.97M |
March 15, 2024 | 236.88M |
March 14, 2024 | 232.05M |
March 13, 2024 | 238.13M |
March 12, 2024 | 234.65M |
March 11, 2024 | 232.79M |
March 08, 2024 | 236.88M |
March 07, 2024 | 237.62M |
March 06, 2024 | 241.70M |
March 05, 2024 | 247.26M |
March 04, 2024 | 240.59M |
March 01, 2024 | 210.90M |
February 29, 2024 | 193.09M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
32.14M
Minimum
Mar 18 2020
400.67M
Maximum
Mar 03 2023
177.88M
Average
175.38M
Median
Enterprise Value Benchmarks
Biophytis SA | 2.615M |
DBV Technologies SA | -30.45M |
Cellectis SA | 64.36M |
Genfit SA | 171.56M |
Biodexa Pharmaceuticals Plc | -3.223M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -5.431M |
Revenue (Quarterly) | 21.12M |
Total Expenses (Quarterly) | 24.87M |
EPS Diluted (Quarterly) | -0.14 |
Gross Profit Margin (Quarterly) | 43.65% |
Profit Margin (Quarterly) | -25.71% |
Earnings Yield | -8.72% |
Normalized Earnings Yield | -8.165 |